期刊文献+

胃癌中HER-2、MT1-MMP及CD147蛋白的表达及意义 被引量:7

Expression of HER-2,MT1-MMP and CD147 in gastric carcinoma and their significances
下载PDF
导出
摘要 目的观察HER-2、MT1-MMP及CD147蛋白在胃癌中的表达和相关性及其与胃癌生物学行为的关系。方法应用免疫组化SABC法检测10例正常胃组织和178例胃癌组织中HER-2、MT1-MMP和CD147蛋白的表达。结果 HER-2、MT1-MMP和CD147蛋白在正常胃组织和胃癌组织的表达差异均有显著性(P<0.05);且它们在分化程度低、侵及浆膜层以及有淋巴结转移的胃癌中的表达均明显高于分化程度高、未侵及浆膜层以及无淋巴结转移胃癌组(P<0.01)。在胃食管连接部的HER-2蛋白表达高于胃部胃癌,HER-2与MT1-MMP蛋白在胃癌中表达有相关性,但差异差异无显著性,Pearson相关系数为0.301(P=0.05)。CD147与MT1-MMP蛋白在胃癌中的表达亦有相关性,Pearson相关系数为0.887(P<0.01)。结论 HER-2、MT1-MMP及CD147蛋白在胃癌中均高表达,HER-2蛋白、CD147蛋白的表达均与MT1-MMP的表达相关,三者可能共同参与胃癌的侵袭和转移。 Purpose To investigate the expression of HER-2, MTI-MMP and CD147 in gastric carcinoma and to find out their correla- tions with the biologic behaviors of the tumor. Methods HER-2, MT1-MMP and CD147 proteins were detected by immunohistochemi- cal staining in 10 cases of normal gastric tissue and 178 cases of gastric carcinoma. Results All of the expression level of HER-2, MT1-MMP and CD147 protein in gastric carcinoma tissues was significantly higher than that in normal gastric tissues (P 〈 0. 05 ). The expression of them in the subgroup of poorly-differentiated with serosal invasion and lymph nodes metastasis was significantly higher than the other subgroup of well-differentiated without serosal invasion and lymph nodes metastasis (P 〈 0. 01 ). And the expression of HER-2 protein in the esophagogastric junction was higher than in the stomach. There was a positive correlation trend between the ex- pression of HER-2 and MT1-MMP protein in gastric carcinoma, but without significant difference, with Pearson coefficient of 0. 301 (P =0. 05). The positive correlation was found between CD147 and MT1-MMP protein in gastric carcinoma, with Pearson coefficient 0. 887 (P 〈 0. 01 ). Conclusions Over-expression of HER-2, MT1-MMP and CD147 is detected in gastric carcinoma, with close re- lationships of HER-2 and CD147 with MT1-MMP, which suggests that all the three proteins may be involved in the invasiveness and metastasis of gastric carcinoma.
作者 苗杰
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2012年第12期1361-1364,共4页 Chinese Journal of Clinical and Experimental Pathology
关键词 胃肿瘤 CD147 MT1-MMP HER-2 免疫组织化学 gastric neoplasms HER-2 MTI-MMP CD147 immunohistochemistry
  • 相关文献

参考文献13

  • 1Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009 [ J]. CA Cancer J Clin, 2009,59(4):225 -49.
  • 2Meert A P, Martin B, Paesmans M, et al. The role of HER-2/neu expressionon the survival of patients with lung cant'er: asystematiereview of the literature [ J ]. Br J Cancer, 2003,89 ( 6 ) :959 - 65.
  • 3Ishibashi Y, Matsumoto T, Niwa M, et al. CD147 and matrix metalloproteinase-2 protein expression as significant prognostic fac- tors in esophageal squamous cell carcinoma [ J ]. Cancer, 2004, 101 (9) :1994 -2000.
  • 4胃癌HER2检测指南[J].中华病理学杂志,2011,40(8):553-557. 被引量:98
  • 5Park Y H, Jung H H, Ahn J S. Ets-I upregulates HER2-indueed MMP-I expression in breast cancer cells [ J ]. Bioehem Biophys Res Commun, 2008,377 (2) :389 - 94.
  • 6Guo H, Li R, Zucker S, et al. EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial colage- nave to the tumor eell surface[ J]. Cancer Res, 2000,60(4) :888 -91.
  • 7Dowdy S C, Mariani A, Jankneeht R. HER-2/neu and TAKI-me- diated up-regulation of the transforming growth factor beta inhibitor Smad7 via the ETS protein ERSI [J]. J Binl Chem, 2003,278 ( 45 ) :44377 - 84.
  • 8Pellikainen J M, Ropponen K M, Kataja V V, et al. Expressinn of matrixmetalloproteinasc MMP-2 and MMP-9 in breast cancer with a special rellrence to activator protein-2, HER-2, and prog- nosis [ J ]. Clin Cancer Res, 2004,10 (22) :7621 - 8.
  • 9Nakamura K, Kodama J, Hongo A, et al. Role of emmprin in en- dometrialcancer[J]. BMC Cancer, 2012,12(1):191.
  • 10Nabeshima K, lwasaki H, Koga K, et al. Emmprin (basigin/ CD147) : matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critieal role in cancer pro- gression [ J ]. Pathol Int, 2006,56 ( 7 ) : 359 - 67.

二级参考文献13

  • 1Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase Ilalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol, 2005, 16(2) :273-278.
  • 2Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol, 2008, 19 (9) : 1523-1529.
  • 3Barros-Silva JD, Leitao D, Afonso L, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer, 2009, 100 ( 3 ) :487-493.
  • 4Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 ( HER2 )-positive advanced gastric cancer ( GC ). J Clin Oncol, 2009, 27 : 18S( suppl : abstr LBA4509 ).
  • 5Bang Y J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (TOGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010, 376(9742) :687-697.
  • 6Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology, 2008, 52(7) :797-805.
  • 7Ruschoff J, Nagelmeier I, Baretton G, et al. Her2 testing in gastric cancer. What is different in comparison to breast cancer? Pathologe, 2010, 31 ( 3 ) :208-217.
  • 8RuschoffJ, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch, 2010, 457 ( 3 ) : 299-307.
  • 9Kim KC, Koh YW, Chang HM, et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol, 2011, In press.
  • 10Boers JE, Meeuwissen H, Methorst N. HER2 status in gastro- oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5 ) and two in situ hybridization methods ( FISH and SISH). Histopathology, 2011, 58 ( 3 ) : 383-394.

共引文献97

同被引文献78

  • 1HER-2研究全国协作组,张瑰红.胃癌中HER-2/neu基因扩增和蛋白表达的多中心研究[J].中华消化杂志,2006,26(10):657-660. 被引量:17
  • 2Seceareccia E, Brodt P. The role of the insulin-like growth factor- 1 receptor in malignancy: an update[ J]. Growth Horm IGF Res, 2012,22(6) :193 -9.
  • 3Reinmuth N, Fan F, Liu W, et al. Impact of insulin-like growth factor receptor-1 function on angiogenesis, growth, and metastasis of colon cancer[ J]. Lab Invest, 2002,82(10) : 1377 - 89.
  • 4Pengchong H, Tao H. Expression of IGF-1 R, VEGF-C and D2-40 and their correlation with lymph node metastasis in endometrial ad- enocarcinoma[J]. Eur J Gynaecol Oncol, 2011,32 ( 6 ) :660 - 4.
  • 5Friedrich R E, Hagel C, Bartel-Friedrich S. Insulin-like growth factor 1 receptor (IGF-1 R) in primary and metastatic undifferenti- ated carcinoma of the head and neck : a possible target of immuno- therapy[ J]. Anticancer Res, 2010,30(5 ) : 1641 - 3.
  • 6Jaquish D V, Yu P T, Shields D J, et al. IGF1-R signals through the RON receptor to mediate pancreatic cancer cell migration[ J]. Carcinogenesis, 2011,32(8) :1151 -6.
  • 7Metalli D, Lovat F, Tripodi F, et al. The insulin-like growth fac- tor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent acti- vation of paxillin[J]. Am J Pathol, 2010,176 (6):2997-3006.
  • 8Hellawell G O, Turner G D, Davies D R, et al. Expression of the type I insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease [J]. Cancer Res, 2002,62 (10) :2942 - 50.
  • 9Stenzinger A, Wittschieber D, van Winterfeld M, et al. High ex- tracellular matrix metallo-proteinase irtducer/CD147 expression is strongly and independently associated with poor prognosis in color- ectal cancer[Jl. Hum Pathol, 2012,43(9) :1471 -81.
  • 10Kanekura T, Chen X. CD147/basigin promotes progression of ma- lignant melanoma and other cancers[J]. J Dermatol Sci, 2010,57 (3) :149 -54.

引证文献7

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部